Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, open-label, continuation trial LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus (SLE) who completed the phase 2 protocol LBSL02

Trial Profile

A multi-center, open-label, continuation trial LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus (SLE) who completed the phase 2 protocol LBSL02

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 15 Nov 2023 Results of post hoc analysis pooled data from the three multicenter LTE studies (112626, 112233, 112234), presented at the ACR Convergence 2023.
    • 15 Nov 2023 Results of comprehensive analysis of infections among BEL-treated patient presented at the ACR Convergence 2023
    • 03 Jun 2023 Results of post-hoc pooled analysis data from three LTE studies BLISS-52 + BLISS-76 LTE (excluding US patients from BLISS-76; Phase 3; GSK Study 112234) assessing long-term safety of belimumab, presented at the 24th Annual Congress of the European League Against Rheumatism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top